ASCO: Diet and Exercise in Cancer Prevention

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.